概要
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
本部
San Francisco, California, USA
設立
2013
種別
研究所
エコシステム
1
法的情報
- 法的名称
- Calico Life Sciences LLC
- 状態
- 活動中
- 確認日
- 2026-08-30
- 次回確認日
- 2026-11-30
ミッション
“Harness advanced technologies to increase human healthspan.”
重点領域
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
戦略ロードマップ
2025 Q4
● 進行中ABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
長寿・アンチエイジング
2026 Q4
◯ 予定Combination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
長寿・アンチエイジング
2028 Q2
◯ 予定Age reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
長寿・アンチエイジング